Outcome after FCR by most-intensive prior therapy
| Prior therapy hierarchy . | No. of patients . | Median no. of prior . | F/Alk refractory, % . | NCI-WG Response (%) . | Median, mo . | ||
|---|---|---|---|---|---|---|---|
| CR + nPR . | OR . | PFS . | OS . | ||||
| Antibody only | 25 | 1 (1-2) | −/− | 64 | 92 | 49 | 69 |
| Fludarabine only | 61 | 1 (1-5) | 11/− | 61 | 80 | 39 | 88 |
| Alkylating agent only | 36 | 1 (1-4) | −/47 | 39 | 78 | 20 | 48 |
| F and alkylating agent, nonconcurrent | 57 | 3 (2-9) | 35/51 | 43 | 74 | 17 | 44 |
| FC, FCR, FCM, FND | 78 | 2 (1-10) | 13/9 | 42 | 73 | 19 | 41 |
| Multiagent (CHOP, ESHAP, DHAP) or SCT | 27 | 3 (1-10) | 63/52 | 11 | 44 | 6 | 20 |
| Prior therapy hierarchy . | No. of patients . | Median no. of prior . | F/Alk refractory, % . | NCI-WG Response (%) . | Median, mo . | ||
|---|---|---|---|---|---|---|---|
| CR + nPR . | OR . | PFS . | OS . | ||||
| Antibody only | 25 | 1 (1-2) | −/− | 64 | 92 | 49 | 69 |
| Fludarabine only | 61 | 1 (1-5) | 11/− | 61 | 80 | 39 | 88 |
| Alkylating agent only | 36 | 1 (1-4) | −/47 | 39 | 78 | 20 | 48 |
| F and alkylating agent, nonconcurrent | 57 | 3 (2-9) | 35/51 | 43 | 74 | 17 | 44 |
| FC, FCR, FCM, FND | 78 | 2 (1-10) | 13/9 | 42 | 73 | 19 | 41 |
| Multiagent (CHOP, ESHAP, DHAP) or SCT | 27 | 3 (1-10) | 63/52 | 11 | 44 | 6 | 20 |
NCI-WG indicates National Cancer Institute-Working Group; CR, complete remission; nPR, nodular partial remission; OR, overall response; PFS, progression-free survival; OS, overall survival; F, fludarabine; Alk, alkylating agent; FC, fludarabine and cyclophosphamide; FCR, fludarabine, cyclophosphamide, and rituximab; FCM, fludarabine, cyclophosphamide, and mitoxantrone; FND, fludarabine, mitoxantrone, and dexamethasone; CHOP, cyclophosphamide, adriamycin, vincristine, prednisone; ESHAP, etoposide, methylprednisone, cytarabine, cisplatin; DHAP, dexamethasone, cytarabine, cisplatin; and SCT, allogeneic or autologous stem cell transplantation.